ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Psoriasis
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: open labelMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg subcutaneously at weeks 0, 4 and 16. At week 16, patients with remaining BSA ?3% will be given HALOG ointment 0.1% to apply BID for 4 weeks. Patients who have ?3% BSA at week 16 will remain on Ilumya monotherapy. Pa...
25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg subcutaneously at weeks 0, 4 and 16. At week 16, patients with remaining BSA ?3% will be given HALOG ointment 0.1% to apply BID for 4 weeks. Patients who have ?3% BSA at week 16 will remain on Ilumya monotherapy. Patients will continue to be evaluated at weeks 20 and 24.
Tracking Information
- NCT #
- NCT04347473
- Collaborators
- Sun Pharmaceutical Industries Limited
- Investigators
- Not Provided
Get Well Soon